<?xml version='1.0' encoding='utf-8'?>
<document id="24810388"><sentence text="Edoxaban: a focused review of its clinical pharmacology."><entity charOffset="0-8" id="DDI-PubMed.24810388.s1.e0" text="Edoxaban" /></sentence><sentence text="Long-term anticoagulation treatment with warfarin has been associated with a number of limitations in clinical practice and there is a need for more convenient long-term anticoagulation treatment" /><sentence text=" One of the non-vitamin K oral anticoagulants in development is edoxaban, a factor Xa inhibitor that is administered once daily"><entity charOffset="16-25" id="DDI-PubMed.24810388.s3.e0" text="vitamin K" /><entity charOffset="64-72" id="DDI-PubMed.24810388.s3.e1" text="edoxaban" /><pair ddi="false" e1="DDI-PubMed.24810388.s3.e0" e2="DDI-PubMed.24810388.s3.e0" /><pair ddi="false" e1="DDI-PubMed.24810388.s3.e0" e2="DDI-PubMed.24810388.s3.e1" /></sentence><sentence text=" The pharmacological properties of edoxaban have various advantages in anticoagulant therapy"><entity charOffset="35-43" id="DDI-PubMed.24810388.s4.e0" text="edoxaban" /></sentence><sentence text=" Edoxaban quickly reaches peak plasma concentrations in 1"><entity charOffset="1-9" id="DDI-PubMed.24810388.s5.e0" text="Edoxaban" /></sentence><sentence text="5 h, has a half-life of 10-14 h, has relatively high bioavailability of 62% and exhibits highly selective, competitive, concentration-dependent inhibition of human factor Xa" /><sentence text=" The plasma concentrations of edoxaban are also closely correlated with suppression of thrombin generation and a range of platelet activation parameters (fragment 1+2, thrombin-antithrombin complex, and β-thromboglobulin), which edoxaban has been shown to rapidly inhibit"><entity charOffset="30-38" id="DDI-PubMed.24810388.s7.e0" text="edoxaban" /><entity charOffset="229-237" id="DDI-PubMed.24810388.s7.e1" text="edoxaban" /><pair ddi="false" e1="DDI-PubMed.24810388.s7.e0" e2="DDI-PubMed.24810388.s7.e0" /><pair ddi="false" e1="DDI-PubMed.24810388.s7.e0" e2="DDI-PubMed.24810388.s7.e1" /></sentence><sentence text=" The anticoagulant activity of edoxaban is not affected by food intake or ethnicity and a number of drug-drug interaction studies have been performed"><entity charOffset="31-39" id="DDI-PubMed.24810388.s8.e0" text="edoxaban" /></sentence><sentence text=" Co-administration of edoxaban with strong P-glycoprotein inhibitors, such as dronedarone, quinidine, and verapamil requires edoxaban dose-reduction by 50% to avoid the risk of over-exposure"><entity charOffset="22-30" id="DDI-PubMed.24810388.s9.e0" text="edoxaban" /><entity charOffset="78-89" id="DDI-PubMed.24810388.s9.e1" text="dronedarone" /><entity charOffset="91-100" id="DDI-PubMed.24810388.s9.e2" text="quinidine" /><entity charOffset="106-115" id="DDI-PubMed.24810388.s9.e3" text="verapamil" /><entity charOffset="125-133" id="DDI-PubMed.24810388.s9.e4" text="edoxaban" /><pair ddi="false" e1="DDI-PubMed.24810388.s9.e0" e2="DDI-PubMed.24810388.s9.e0" /><pair ddi="false" e1="DDI-PubMed.24810388.s9.e0" e2="DDI-PubMed.24810388.s9.e1" /><pair ddi="false" e1="DDI-PubMed.24810388.s9.e0" e2="DDI-PubMed.24810388.s9.e2" /><pair ddi="false" e1="DDI-PubMed.24810388.s9.e0" e2="DDI-PubMed.24810388.s9.e3" /><pair ddi="false" e1="DDI-PubMed.24810388.s9.e0" e2="DDI-PubMed.24810388.s9.e4" /><pair ddi="false" e1="DDI-PubMed.24810388.s9.e1" e2="DDI-PubMed.24810388.s9.e1" /><pair ddi="false" e1="DDI-PubMed.24810388.s9.e1" e2="DDI-PubMed.24810388.s9.e2" /><pair ddi="false" e1="DDI-PubMed.24810388.s9.e1" e2="DDI-PubMed.24810388.s9.e3" /><pair ddi="false" e1="DDI-PubMed.24810388.s9.e1" e2="DDI-PubMed.24810388.s9.e4" /><pair ddi="false" e1="DDI-PubMed.24810388.s9.e2" e2="DDI-PubMed.24810388.s9.e2" /><pair ddi="false" e1="DDI-PubMed.24810388.s9.e2" e2="DDI-PubMed.24810388.s9.e3" /><pair ddi="false" e1="DDI-PubMed.24810388.s9.e2" e2="DDI-PubMed.24810388.s9.e4" /><pair ddi="false" e1="DDI-PubMed.24810388.s9.e3" e2="DDI-PubMed.24810388.s9.e3" /><pair ddi="false" e1="DDI-PubMed.24810388.s9.e3" e2="DDI-PubMed.24810388.s9.e4" /></sentence><sentence text=" The exposure of edoxaban may also increase in patients with a body weight ≤60 kg and moderate renal impairment"><entity charOffset="17-25" id="DDI-PubMed.24810388.s10.e0" text="edoxaban" /></sentence><sentence text=" This meant a dose-reduction strategy in patients at risk of over-exposure was utilized in Phase III clinical studies" /><sentence text=" In conclusion, the pharmacological properties of edoxaban provide rapid and specific inhibition of factor Xa, which is closely related to plasma concentrations"><entity charOffset="50-58" id="DDI-PubMed.24810388.s12.e0" text="edoxaban" /></sentence><sentence text=" Given the limitations with long-term warfarin therapy, once-daily edoxaban may provide a convenient long-term alternative for patients"><entity charOffset="67-75" id="DDI-PubMed.24810388.s13.e0" text="edoxaban" /></sentence><sentence text=" " /></document>